Shots:
- The post hoc analysis of P-III (REDEFINE 1) trial assessed CagriSema (cagrilintide 2.4mg & semaglutide 2.4mg) vs PBO & individual components effects on CV risk factors in 3,417 obese/overweight pts with ≥1 obesity-related comorbidities, & without T2D
- Trial showed CagriSema reduced systolic BP by -10.9 mmHg over 68wks. (vs -8.8 with semaglutide, & -2.1 with PBO), regardless of BMI, with ~4/10 CagriSema-treated pts reducing or stopping BP medications during the trial
- Trial showed reduced hsCRP by 68.9% at Wk. 68 (vs 55.4% with semaglutide, 16% with PBO); mediation analysis found this effect was partly independent of weight loss, & CagriSema also reduced the proportion of pts at 10-year intermediate-to-high ASCVD risk; data presented at ObesityWeek & published in Hypertension
Ref: Novo Nordisk | Image: Novo Nordisk | Press Release
Related News:- Metsera Declares Novo Nordisk’s ~$9B Acquisition Proposal a Superior Offer to Pfizer Merger Agreement
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
